Trial Profile
An Observational Study To Determine Velcade (Bortezomib) Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies (ADVANCE)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Apr 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms ADVANCE
- Sponsors Janssen-Cilag
- 15 Apr 2015 Status changed from discontinued to completed as reported by ClinicalTrials.gov record.
- 04 Nov 2010 Planned End Date changed from 1 Apr 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
- 27 Apr 2010 Actual patient number (11) added as reported by ClinicalTrials.gov.